Jardiance Reduces Risk of Cardiovascular Events in Adults With Type 2 Diabetes

Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance reduced the risk of cardiovascular events in adults with Type 2 diabetes who are at high risk of such events, making it the only glucose-lowering agent to demonstrate this benefit in a dedicated trial.

In a long-term study of more than 7,000 patients, Jardiance combined with like antihypertensive and lipid-lowering agents met its primary endpoint of slowing the time to first occurrence of CV death, nonfatal myocardial infarction or nonfatal stroke.

The study compared Jardiance plus the standard of care CV drugs with placebo and the same CV drugs, the firms said Wednesday. They plan to present detailed results Sept. 17 at the European Association for the Study of Diabetes annual meeting.

Roughly 50 percent of deaths in people with Type 2 diabetes worldwide are caused by cardiovascular disease, according to Hans-Juergen Woerle, BI’s global vice president of medicine.

Lilly spokeswoman Molly McCully says the firms will share data with global regulators. — Kellen Owings